Inspira Technologies (IINN) Releases Favorable Data on VORTX
https://www.zacks.com/stock/news/2240756/inspira-technologies-iinn-releases-favorable-data-on-vortx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240756
Mar 14, 2024 - Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2240683/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240683
Mar 14, 2024 - Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
0
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
https://www.zacks.com/stock/news/2242255/chemed-che-reaches-a-new-52-week-high-what-s-driving-it?cid=CS-ZC-FT-analyst_blog|52-week_high/low-2242255
Mar 18, 2024 - Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
0
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
https://www.zacks.com/stock/news/2245088/tandem-diabetes-tndm-gains-from-innovation-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2245088
Mar 22, 2024 - Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
0
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
https://www.zacks.com/stock/news/2245968/charles-river-crl-extends-gene-therapy-deal-with-nus-medicine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245968
Mar 26, 2024 - Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
0
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
https://www.zacks.com/stock/news/2246920/here-s-why-you-should-buy-zimmer-biomet-zbh-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2246920
Mar 27, 2024 - Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.
0
Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues
https://www.zacks.com/stock/news/2248459/tandem-diabetes-tndm-gains-from-innovation-amid-macro-issues?cid=CS-ZC-FT-analyst_blog|zer_report_update-2248459
Apr 01, 2024 - Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.
0
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
https://www.zacks.com/stock/news/2248449/paragon-28-fna-expands-syndesmotic-repair-line-with-new-launch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2248449
Apr 01, 2024 - The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
0
Here's Why Investors Should Buy ResMed (RMD) Stock Now
https://www.zacks.com/stock/news/2248659/here-s-why-investors-should-buy-resmed-rmd-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2248659
Apr 01, 2024 - Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.
0
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
https://www.zacks.com/stock/news/2249325/here-s-why-investors-should-retain-labcorp-lh-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2249325
Apr 02, 2024 - Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
0